v3.25.2
Description of Business, Basis of Presentation, and Summary of Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
ProductCategory
Customer
Jun. 30, 2024
USD ($)
Customer
Jun. 30, 2025
USD ($)
ProductCategory
Customer
Segment
Jun. 30, 2024
USD ($)
Customer
Dec. 31, 2024
USD ($)
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Accumulated deficit $ 110,812,000   $ 110,812,000   $ 110,685,000
Number of reporting segments | Segment     3    
Intangible assets useful life 15 years   15 years    
Number of revenue-generating operating segments | Segment     2    
Number of product categories | ProductCategory 2   2    
Description of payment terms     The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments: the biomedical market segment (LCT) and anti-aging market segment (LSC). The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, which are sold both domestically within the United States and internationally. The anti-aging market segment markets and sells a line of skin care products directly to customers through online orders via the ecommerce sales channel.    
Product return guarantee period     30 days    
Allowance for sales returns $ 0 $ 0 $ 0 $ 0  
Reduction in qualified research and development expenses 52,000 $ 84,000 52,000 $ 84,000  
FDIC secured limit, amount 250,000   250,000    
Cash, FDIC insured amount $ 198,000   $ 198,000   $ 327,000
Customer Concentration Risk [Member] | Major Customer [Member] | Accounts Receivable, Net [Member]          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage     66.00%   67.00%
Australian Taxation Office [Member]          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Percentage of refundable tax credit on qualified research and development     43.50%    
Maximum [Member]          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Estimated useful life of property and equipment 5 years   5 years    
Sales commissions amortization period     1 year    
Minimum [Member]          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Estimated useful life of property and equipment 3 years   3 years    
Product Sales [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Number of customers more than ten percentage of revenue | Customer 1        
Product Sales [Member] | Customer Concentration Risk [Member] | Major Customer [Member] | Revenue, Segment Benchmark          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage 52.00% 53.00% 54.00% 53.00%  
Biomedical Market [Member] | Customer Concentration Risk [Member] | Revenue, Segment Benchmark          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Number of customers more than ten percentage of revenue | Customer   1 1 1  
Biomedical Market [Member] | Customer Concentration Risk [Member] | Major Customer [Member] | Revenue, Segment Benchmark          
Description Of Business Basis Of Presentation And Summary Of Significant Accounting Policies [Line Items]          
Concentration risk percentage 55.00% 59.00% 57.00% 58.00%